ProBioGen has signed a Master Service Agreement (MSA) with Zag Bio Inc., a biotechnology company developing thymus-targeted therapies to induce central immune tolerance.

Under the MSA’s first integrated service package, ProBioGen will provide cell line development, process development, and GMP manufacturing for Zag Bio’s lead ZAG-101 product candidate for the prevention or delay of Type 1 diabetes, targeted to enter clinical development in the second half of 2026.

“This agreement is more than a contractual milestone. It marks the beginning of a collaborative effort to bring Zag Bio’s highly innovative thymus-targeted bifunctional antibody program to life,” said Dr. Alfred Merz, CEO, ProBioGen. “Our integrated platform combines cutting-edge technologies, harmonized automated workflows, and cross-functional expertise, across development and manufacturing, to accelerate our partner’s biologics programs with precision and flexibility.”

“We chose ProBioGen not just for their scientific excellence, but for their reputation as a truly collaborative and flexible partner,” added Jason Cole, CEO, Zag Bio, “They  impressed us with their deep understanding and integrated capabilities in Fc-fusion protein development, which will enable the manufacturing and clinical development of our lead ZAG-101 molecule, to potentially  deliver transformative impact to patients with Type 1 diabetes and over time, additional autoimmune diseases.”

Financial details of the agreement were not disclosed.